Welcome

About Mucosis

Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM®, an intranasal vaccine to prevent respiratory syncytial virus infection. Our vaccines are based on the patented and validated Mimopath® technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in our proof-of-concept animal and human studies of our FluGEM® vaccine candidate

 

Contact Contact

16.05.13 Mucosis presents preclinical data demonstrating protection by its intranasal SynGEM® RSV vaccine candidate
more >

08.10.12 Mucosis signs Research and License Option Agreement with Crucell
more >

25.09.12 ExpreS²ion, Mucosis, and University of Copenhagen receive Eurostars grant
more >

18.09.12 Mucosis Appoints Thomas Johnston to CEO
more >

10.05.12 Mucosis announces positive proof-of-concept data for Mimopath® platform in humans
more >

03.05.12 Mucosis announces publication of preclinical data demonstrating...
more >

15.11.11 Mucosis announces new scientific advisory board
more >

17.05.11 Mucosis appoints Thomas Johnston as Chief Business Officer
more >